الفهرس 
AcknowledgementOnly 14 pages are availabe for public view
 |  | from | 121 |  |  |
| | | from | 121 | | |
Abstract
Epilepsy treatment is often for years or even life long .Valproate (VPA) is abroad spectrum antiepileptic drug. The commonest side effect is weight gain and increased BMI.
Our study aims to estimate the level of serum insulin and leptin in idiopathic epileptic children treated with valproate (monotherapy) and correlate their levels with body mass index.
This prospective study was conducted on 20 patients with idiopathic epilepsy attending to outpatient neuropediatric clinic in Benha University Hospita.All children included in the study were subjected to clinical history taking, complete physical and neurological examination and anthropometrics measurements including weight, height, body mass index and laboratory investigations including insulin and leptin levels before and after treatment with VPA.
Our study revealed that
As regard to BMI there was a highly statistical significant difference in epileptic children treated after VPA (monotherapy) for 4 months compared to same epileptic children before treatment.
As regard levels of insulin and leptin there was a highly significant statistical difference in epileptic children after VPA(monotherapy) for 4 months compared to same epileptic children before treatment.
There was a significantly positive correlation between BMI and serum level of insulin and leptin. So, we concluded that valproate causes weight gain that is possibly due to multiple endocrinological mechanisms.